# Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

> **NCT04831710** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 83 (estimated)

## Conditions studied

- Angioimmunoblastic T-cell Lymphoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT04831710
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-15
- **Primary completion:** 2022-04-15
- **Final completion:** 2023-04-15
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04831710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04831710, "Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04831710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*